A PD-1/LAG-3 bispecific antibody has been approved for melanoma, with numerous trials ongoing across other malignancies.<h4>Conclusion</h4>Despite demonstrated efficacy, challenges including variable response rates, resistance mechanisms, and immune-related adverse events remain. This evidence concerns the gene LAG3 and melanoma.